A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Latest Information Update: 17 Dec 2023
At a glance
- Drugs Uproleselan (Primary) ; Melphalan
- Indications Gastrointestinal disorders; Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2023 Results(n=50) presented at the 65th American Society of Hematology Annual Meeting and Exposition, discussing clinically significant improvement in GI-toxicity related symptoms as assessed via PRO-CTCAE in patients with MM undergoing melphalan-conditioned AHCT, when compared to placebo+SoC.
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 31 Oct 2022 Planned End Date changed from 31 Dec 2022 to 7 Nov 2022.